Therapeutics
HTG leverages its transcriptomic and epi-transcriptomic profiling technology to dramatically transform the drug discovery process.
Our Technology
HTG leverages its transcriptomic and epi-transcriptomic profiling technology to dramatically transform the drug discovery process. HTG's platform currently produces a profile with nearly 42,000 data points per sample in three independent data sets and has the ability to detect changes in RNA modifiations, such as N6-methyladenosine (m6A), which has been increasingly implicated in various disease states.
HTG is focused on utilizing its innovative technology platforms to create an entirely new generation of drug discovery tools aimed at developing therapeutic candidates with superior efficacy and safety profiles - transforming the process across a broad range of disease areas including oncology, immunology, diabetes, and rare diseases, among others.
HTG EdgeSeq and Epi-EdgeSeq technology enables a more highly resolved view of the transcriptome, especially aberrations in the physiological states leading to disease. By assimilating sophisticated RNA profiling and advanced medical chemistry technologies directly - and early-on - in the process, researchers can access critical learnings much sooner, significantly reduce risk, and increase successful outcomes.
Drug Discovery Process
By leveraging HTG's unique profiling technologies earlier in the drug discovery process, HTG Therapeutics is expected to generate lead compounds faster, and with superior efficacy and toxicity profiles.
